Analytical Data
-
Gene name
EPHA2
- Application
-
Alternative Names
EPHA2；ECK;Ephrin type-A receptor 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P29317
-
Expression Region
24-534aa
-
AA Sequence
AQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGN
-
Molecular Weight
61.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPHA2, an epidermal growth factor receptor (EGFR) family member, has garnered significant interest in cancer research due to its role in tumorigenesis, progression, and metastasis. As a receptor tyrosine kinase, EPHA2 is implicated in various cellular processes including cell mobility, adhesion, and survival. Abnormal expression and activation of EPHA2 have been linked to multiple cancer types, such as breast, prostate, and lung cancers, making it a potential biomarker and therapeutic target. The exploration of EPHA2 recombinant proteins facilitates the understanding of its signaling pathways and interactions, providing insights into its function in oncogenesis. Researchers have developed EPHA2 reconstructions to investigate receptor dynamics, ligand binding, and downstream signaling mechanisms in cellular models. These recombinant proteins are crucial for high-throughput screening of small-molecule inhibitors, ultimately leading to targeted therapies. Additionally, characterizing the structural dynamics of EPHA2 through recombinant techniques aids in elucidating its role in maintaining tumor microenvironments. With the overarching goal of improving cancer treatment outcomes, ongoing studies on EPHA2 recombinant proteins aim to uncover novel intervention strategies and enhance the development of personalized therapies for patients. This body of research highlights the importance of EPHA2 as both a biomarker for tumor diagnosis and a promising target for innovative cancer therapies.
